Objective: This study aimed to assess the prevalence of pain in patients with RA in clinical remission and analyze the demographic and clinical characteristics of those who experienced persistent pain despite remission status. Methods: Data from 1,891 patients with RA registered on the Korean College of Rheumatology Biologics and Targeted Therapy registry were obtained. Remission was defined as a Disease Activity Score of 28 joints-erythrocyte sedimentation rate (ESR) <2.6.Pain intensity was classified as severe (pain visual analog scale [VAS] ≥7), moderate (4≤VAS<7), or mild (VAS <4). Results: Our analysis showed that 52.6% of patients complained of severe pain at the start of or during switching biological disease-modifying anti-rheumatic drugs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). Despite having a 36.0% (n=680) remission rate after the use of bDMARDs or tsDMARDs at their 1-year follow-up, 21.5% (n=146) of these patients had moderateto-severe pain, higher frequency of foot erosions, and comorbidities, such as mental illness, endocrine, renal, and neurological disorders, than patients with a milder degree of pain. The multivariable regression analysis showed that presence of foot erosions, neurological disorders, and use of corticosteroids were independently associated with moderate-to-severe pain in patients with RA despite being in remission. The level of ESR and use of Janus kinase inhibitors were inversely associated with moderate-to-severe pain. Conclusion Persistent pain and discomfort continue to be a problem for patients with RA in clinical remission. Continued research on insistent pain in patients with RA is warranted to better alleviate distress and improve the quality of life in patients.

Henoch-Sch nlein purpura is a small-vessel vasculitis characterized by palpable purpura, abdominal pain, hematuria and arthralgia. Joint involvement occurs in 2/3 of the cases and the joint symptoms are misapprehended as an orthopaedic problem because they are often severe and occurs before characteristic purpura. It has been reported that the joint symptoms can be improved without any sequelae. But, recently some authors suggest that severe joint destruction can occur when combined with rheumatoid arthritis and the patients are FILA-DR4 positive. So, the regular follow-up for joint symptoms and screening test for the risky patients having possibility for progression of arthritis are required. In order to increase the attention of the orthopaedic surgeons on this disease and study the progression of joint symptoms, possibility of development of screening test for the risky patients and the characterisitics of the disease, we analyzed the 58 patients of Henoch-Sch nlein purpura. The following results were obtained. Among 58 patients 34 cases were male and 25 cases were female, 5 to 10-year-old children were affected more frequently and the disease occurs frequently in spring and winter season. Joint symptoms developed in 22/58 patients(37.9%) and occurs before characteristic purpura in 5/22 patients(22.7%) among the joint symptom-developed patients. Knee and ankle were affected in most patients and the inflammatory signs such as high fever, leukocytosis and elevated ESR were accompanied with joint symptom, so it resembled the symptoms and signs of pyogenic arthritis. Most of the patients recovered without remaining sequelae but 9 patients(15.5%) among joint symptom-developed patients complained repeated attacks of arthralgia. The HLA B27 were all positive in those patients. So, it was assumed that the joint symptom in Henoch-Sch nlein purpura has a correlation with genetic environment and through the broad prospective study, the HLA typing can be a screening test for the risky group prone to suffer from repeated attack or aggravation of arthritis.
Abdominal Pain ; Ankle ; Arthralgia ; Arthritis ; Arthritis, Rheumatoid ; Child ; Female ; Fever ; Follow-Up Studies ; Hematuria ; Histocompatibility Testing ; Humans ; Joints* ; Knee ; Leukocytosis ; Male ; Mass Screening ; Purpura* ; Seasons ; Vasculitis

OBJECTIVES: The purpose of this study was to test the reliability and validity of the Korean translation of Gambling Symptom Rating Scale (KG-SAS). METHODS: Using self-report sampling, we eventually included 231 subjects and analysed 70 subjects. These subjects were tested for KG-SAS and the Korean version of Barratt Impulsiveness Scale (BIS). RESULTS: In the reliability test, Cronbach's alpha coefficient was .913 which provided the evidence for the internal consistency. Content validity was assessed with factor analysis and two factors were extracted. Compared with the original scale, both scales embody the same theoretical conceptualization. To assess the validity of the KG-SAS, correlation coefficient was calculated between the KG-SAS and the Korean version of BIS. We got the result that there was a correlation between the KG-SAS and the Korean version of BIS (p<0.01). CONCLUSION: The results of the present study support that the KG-SAS is a reliable and valid scale for evaluating pathological gambling symptom assessment. Based on the results, this study suggests that KG-SAS would be a promising measurement to treat and study pathological gambling.
Gambling* ; Reproducibility of Results* ; Symptom Assessment* ; Weights and Measures

Background: Clinical characteristics and manifestations of psoriatic arthritis (PsA) have been extensively studied in western countries, yet data of Korean patients with PsA are very limited. We aimed to investigate the clinical traits of patients with PsA and dissect the characteristics of those with axial involvement. Methods: In this observational study, we analyzed clinical data of 109 patients with PsA who were enrolled in the Korean College of Rheumatology Biologics and Targeted Therapy registry between December 2012 and March 2022 at the time point of initiating or switching to a biologic agent. Data from 2,221 patients with ankylosing spondylitis (AS) registered during the same period were also analyzed. We divided patients with PsA into patients with or without axial involvement and then added AS patients with psoriasis (total three subgroups) for comparative analyses. Results: Asymmetric oligoarthritis was the most common clinical manifestation in patients with PsA, followed by symmetric polyarthritis and spondylitis. Our analysis indicated that methotrexate and sulfasalazine were the two most prescribed disease-modifying antirheumatic drugs for patients with PsA before starting biologic therapy. The patients with psoriatic spondylitis had more peripheral joint involvement (P = 0.016), less prior uveitis (P < 0.001), and lower human leukocyte antigen B27 (HLA-B27) positivity (P < 0.001) than the AS patients with psoriasis. Furthermore, syndesmophytes and radiographic sacroiliitis were prevalent among patients with PsA and AS patients with psoriasis who had the HLA-B27 gene. Conclusion Our study shows that the degree of peripheral arthritis is less severe in Korean patients with PsA who require biologics and reestablishes that psoriatic spondylitis is a common and important clinical pattern in Korean patients with PsA.

In experimental sutureless muscle surgery with tissue adhesives, current materials have inadequate adhesive strength in the early postoperative period.We performed a modified muscle surgery using a stitch combined with Tisseel (Immuno AG, Vienna, Austria)in order to evaluate the adhesive strengh as a replacement for conventional suture techniques in muscle surgery. Thirty eyes of 15 rabbits were used.We recessed superior and inferior rectus muscles by three different methods, Tisseel only, a stitch with Tisseel, and a stitch only, in each group of 5 rabbits.Conjunctival incisions were closed with the remaining Tisseel in 7 rabbits, and with vicryl in 8 rabbits. Tensile strength of the scleral reattachment site was measured and conjunctival closure was examined by slit-lamp biomicroscopy, at intervals of 1 hour, 12 hours, 1 day, 3 days and 5 days. The strengths of a stitch with Tisseel at each interval were 83.25 +/-1 4 .0 6 gm, 137.50 +/-22.88 gm, 169.75 +/-23.95 gm, 151.50 +/-41.99 gm, and 265.50 +/- 25.01 gm, respectively.The strengths of Tisseel alone were 61.50 +/-2 0 .2 1 gm, 101.50 +/-11.00 gm, 113.25 +/-28.69 gm, 120.50 +/-18.36 gm, and 222.75 +/- 57.67 gm.They were 52.25 +/-24.85 gm, 89.50 +/-16.05 gm, 130.75 +/-21.98 gm, 1 5 3 .7 5 +/-30.35 gm, and 261.50 +/-60.47 gm at each interval in rabbits with a stitch alone. These results showed that the tensile strengths of a stitch with Tisseel were stronger than those of the other two methods up to 1 day after surgery.Even at postoperative 12 hours, the strength was more than 130 gm which was strong enough for scleral attachment.All of the conjunctival closures with Tisseel were well maintained without any complication up to 5 days, the same as vicryl sutures. In conclusion, this study revealed that muscle attachment to the sclera by a stitch with Tisseel was simpler and safer than classical sutures with reduced risk of sclera perforation.Its strong tensile strength at early postoperative days suggests that the method might be considered as an alternative method to classical reattachment using suture material and also that conjunctiva could be closed with Tisseel remnant.
Adhesives ; Conjunctiva ; Fibrin Tissue Adhesive ; Muscles ; Polyglactin 910 ; Rabbits* ; Sclera ; Suture Techniques ; Sutures ; Tensile Strength ; Tissue Adhesives*

Congenital central hypoventilation syndrome (CCHS) is a life-threatening disorder with apnea and cyanosis during sleep requiring immediate endotracheal intubation during the first day of life. The PHOX2B gene has been identified as the major gene involved in CCHS. This is the first report of a Korean neonate with CCHS confirmed to have a PHOX2B mutation with expanded alleles containing 20 polyalanine repeats that is a relatively small number compared to previous cases. The patient required intermittent ventilator support during sleep only and did not suffer from any other disorders of the autonomic nerve system. He consistently needs ventilator support during sleep and remains alive. Analysis of PHOX2B gene is useful for diagnosis and appropriate therapeutic intervention of CCHS patients.
Alleles ; Asian Continental Ancestry Group/*genetics ; Genotype ; Homeodomain Proteins/*genetics ; Humans ; Hypoventilation/congenital/*genetics ; Infant, Newborn ; Male ; Mutation ; Peptides/genetics ; Republic of Korea ; Sequence Analysis, DNA ; Transcription Factors/*genetics ; Ventilators, Mechanical

Translocation between chromosomes 1 and 19 is well documented in ALL. Here, we report a case of refractory anemia with ring sideroblasts associated with marked thrombocytosis with der(19)t(1;19). A 67-yr-old man was admitted to our hospital with anemia and thrombocytosis. The aspirated bone marrow showed erythroid and megakaryocytic hyperplasia and dyspoiesis. Iron staining showed that the ring sideroblasts increased in number. Bone-marrow cell karyotyping showed 46,XY,der(19)t(1;19)(q23;p13)[9]/46,XY,del(5)(q21)[2]/46,XY[9]. PCR analysis showed the absence of the TCF3-PBX1 rearrangement. The patient was treated with hydroxyurea and intermittent blood transfusion. It is known that t(1;19)(q23;p13) leads to a TCF3-PBX1 fusion gene, whose product is a powerful transcriptional activator that plays a key role in the development of ALL. However, t(1;19) has rarely been reported in myeloid neoplasms and the TCF3-PBX1 fusion gene has not been detected. This implies that other genes might be involved in the TCF3-PBX1 rearrangement, or an alternative TCF3-PBX1 fusion transcript with a different breakpoint has not been detected to date. Further research and case studies, including the use of molecular analysis techniques, are required to evaluate the clinical and prognostic significance of t(1;19) in the development of myeloid neoplasms.
Anemia ; Anemia, Refractory ; Blood Transfusion ; Bone Marrow ; Humans ; Hydroxyurea ; Hyperplasia ; Iron ; Karyotyping ; Polymerase Chain Reaction ; Thrombocytosis

BACKGROUND: Hematologic changes in burned patients show unique patterns with time after burn injury. In this study, we analyzed the changes of leukocyte count, hemoglobin concentration, and platelet count according to elapsed time and burn size. METHODS: A total of 265 burned patients were included in this retrospective study. The changes in leukocyte count, hemoglobin, and platelet count according to elapsed time were analyzed every 6 hours from immediately after burn injury until day 2, and then every 24 hours from day 3 to day 14. The differences according to burn size were also analyzed. All the results were expressed as mean+/-standard deviation. RESULTS: Leukocyte count, hemoglobin, and platelet count began to increasing immediately after burn injury, reaching the peak within 12 hours after injury, and then decreased. WBC count was lowest at days 3 to 4 and then began increasing, reaching the second peak at day 7-8. Hemoglobin level continuously decreased and remained at the level of anemia from day 4 to day 14. Platelet count was lowest at days 3-4 and then continuously increased until day 14. The wider the burn sizes were, the greater the changes in leukocyte count, hemoglobin, and platelet count, with 11-40% of the patients showing the most remarkable increase in the number of platelets after day 4. CONCLUSIONS: The leukocyte count, hemoglobin concentration and platelet count were dramatically changed within the first 72 hours after burn injury and the wider the burn sizes were, the greater these changes were. These results could be used as reference data for interpreting the results of complete blood count in burned patients.
Anemia ; Blood Cell Count ; Blood Platelets ; Burns ; Hemoglobins ; Humans ; Leukocyte Count ; Leukocytes ; Platelet Count ; Retrospective Studies

BACKGROUND: Since the genes encoding glycosyltransferases synthesizing ABO antigens were cloned and sequenced in 1990, genetic polymorphisms and phenotype-genotype correlations have been reported by several investigators, but the genetic basis remains unclear for many subgroups. The Ael phenotype is one of the important A subgroups having very weak A antigen, and recent studies suggested that different alleles can result in this phenotype. METHODS: Three unrelated Ael subgroup samples from Korean blood donors were studied. Exons 6 and 7 of the ABO gene, 91% of the catalytic active part of the glycosyltransferase, were amplified and subjected to direct sequencing. RESULTS: Only C467T substitution in comparison with the consensus sequence of A gene was found in one Ael sample, but this mutation pattern was very commonly observed in normal A1 phenotype of Orientals. The other two samples had T646A (Phe216Ile) and G681A (silent) substitutions beside C467T substitution, reported first from a Japanese Ael individual. CONCLUSIONS: These results indicate that molecular genetic heterogeneity within the Ael subgroup was also seen.
ABO Blood-Group System* ; Alleles ; Asian Continental Ancestry Group ; Blood Donors ; Clone Cells ; Consensus Sequence ; Exons ; Genes, vif ; Glycosyltransferases ; Humans ; Molecular Biology ; Phenotype* ; Polymorphism, Genetic ; Population Characteristics ; Research Personnel

Acute promyelocytic leukemia (APL) is considered as a curative disease after combined chemotherapy based on all-trans retinoic acid (ATRA) and anthracycline. However, as long-term survivors continue to increase, reports on sporadic cases of therapy-related myeloid neoplasm (t-MN) after successful APL treatment are also increasing. Recently, we have experienced one patient who developed t-MN 7 yr after APL diagnosis. Even though he had not been exposed to alkylating agents at all, he showed alkylating agents-associated features such as long latency period (>5 yr), first presentation as myelodysplatic phase (multilineage dysplasia with increased blasts), and complex karyotype including monosomy 5 and 7. He received only supportive care and expired 3 months after the diagnosis of t-MN (6 months of survival after the onset of cytopenias). t-MN after complete remission of APL is a rare but fatal complication, and patients with complex karyotypes show ominous prognosis in particular. For the early diagnosis of t-MN, long-term and close monitoring of the patient is needed. One should suspect this late complication whenever any unknown cytopenia develops, and should perform bone marrow biopsy and cytogenetic analysis.
Alkylating Agents ; Biopsy ; Bone Marrow ; Cytogenetic Analysis ; Early Diagnosis ; Humans ; Karyotype ; Latency Period (Psychology) ; Leukemia, Promyelocytic, Acute ; Monosomy ; Prognosis ; Survivors ; Tretinoin